Back to dashboard
CommercialCoverageMedium impact

08.02.23a, Tislelizumab-jsgr (Tevimbra®)

Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Jun 1, 2026
We identified it
Jun 19, 2026
Days to comply
—

Summary

Medical necessity criteria for Tislelizumab-jsgr (Tevimbra®) have been updated for commercial plans. This affects coverage requirements for this oncology medication used in cancer treatment.

Action Required

Action needed
Before June 1, 2026: Billing team and providers must review updated medical necessity criteria for Tislelizumab-jsgr (Tevimbra®) prescriptions. Update prior authorization workflows and documentation requirements in billing system. Ensure providers document compliance with new medical necessity criteria to avoid claim denials.

Related policy hubs